Stockscreener 앱 받기
4.19
9.11%
0.35
시간 외 거래:
4.19
전일 마감가:
$3.84
열려 있는:
$3.86
하루 거래량:
59,570
Relative Volume:
1.17
시가총액:
$12.65M
수익:
$2.38M
순이익/손실:
$-12.40M
주가수익비율:
-0.6483
EPS:
-6.4626
순현금흐름:
$-18.68M
1주 성능:
-11.42%
1개월 성능:
-41.25%
6개월 성능:
-72.66%
1년 성능:
-76.72%
1일 변동 폭
$3.86
$4.49
1주일 범위
$3.77
$4.90
52주 변동 폭
$3.77
$22.20
Femasys Inc Stock (FEMY) Company Profile
명칭
Femasys Inc
전화
770-500-3910
주소
3950 JOHNS CREEK COURT, SUWANEE
Compare FEMY vs ISRG, BDX, ALC, MDLN, RMD
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
FEMY
Femasys Inc
|
4.19 | 12.02M | 2.38M | -12.40M | -18.68M | -6.4626 |
ISRG
Intuitive Surgical Inc
|
402.18 | 147.53B | 10.58B | 3.00B | 2.83B | 8.2437 |
BDX
Becton Dickinson Co
|
141.61 | 40.10B | 21.37B | 1.41B | 3.07B | 3.9437 |
ALC
Alcon Inc
|
64.14 | 32.33B | 10.63B | 819.00M | 1.59B | 1.6577 |
MDLN
Medline Inc
|
36.42 | 31.57B | 29.14B | 1.07B | 1.05B | 1.1956 |
RMD
Resmed Inc
|
186.29 | 27.96B | 5.54B | 1.52B | 1.74B | 10.37 |
Femasys Inc Stock (FEMY) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-11-20 | 개시 | Laidlaw | Buy |
Femasys Inc 주식(FEMY)의 최신 뉴스
FEMY Stock Price, Quote & Chart - ChartMill
FEMY Q1 2026 Earnings: EPS Surprises to the Upside as Narrower Loss Drives Stock HigherBalance Sheet Strength - newsline.com
Femasys Inc. (FEMY) Edges Higher as Stock Tests Key Resistance LevelsWMA Signal - newsline.com
Femasys, Inc. Hits New 52-Week Low at $5.08 Amid Market Challenges - MarketsMojo
Femasys Inc. (FEMY) Q1 2026 Earnings: EPS Surprises to the Upside Despite Stock DeclineEstimate Dispersion - newsline.com
Femasys Inc. (FEMY) Shares Decline 14% as Price Tests Support Near $0.29Dark Pool Prints - newsline.com
Femasys Announces 1-for-20 Reverse Stock Split Implementation - TipRanks
Femasys (NASDAQ: FEMY) implements 1-for-20 reverse stock split - Stock Titan
Femasys (FEMY) Slides 2.96% as Shares Test Key Support LevelVolume Spike Alerts - newsline.com
Femasys Announces 1-for-20 Reverse Stock Split Initiative - TipRanks
Femasys to implement 1-for-20 reverse stock split; trading symbol FEMY unchanged - TradingView
Reverse split will consolidate Femasys (NASDAQ: FEMY) common shares 20-to-1 - Stock Titan
Femasys, Inc. Financial Disclosures & SEC Filings - TradingView
Femasys Inc. (FEMY) Q1 2026 Earnings: Narrower-Than-Expected Loss Highlights Cost Discipline Amid Revenue UncertaintyRevenue Growth Report - newsline.com
FEMY Technical Analysis & Stock Price Forecast - Intellectia AI
Femasys Inc. (FEMY) Edges Higher as Key Support Holds at $0.37Technical Analysis Picks - The Legal Advocate
Femasys Inc. (FEMY) Edges Higher: Navigating Key Support and Resistance LevelsCumulative Volume - newsline.com
Femasys Inc. (FEMY) Q1 2026 Earnings: EPS Beat Drives 29.85% Stock SurgeMid-Term Outlook - newsline.com
Femasys Analyst Ratings and Price Targets | NASDAQ:FEMY - Benzinga
Femasys Jumps Almost 30% as Nasdaq Deadline Remains - TechStock²
FEMY Technical Analysis | Trend, Signals & Chart Patterns | FEMASYS INC (NASDAQ:FEMY) - ChartMill
Maxim Group Maintains Femasys(FEMY.US) With Buy Rating, Maintains Target Price $1.5 - Moomoo
Femasys Expands Fertility Care Portfolio in Europe with CE Mark Approval for FemHSG™ Catheter - Sahm
Analysts Offer Insights on Healthcare Companies: Femasys (FEMY) and Protara Therapeutics (TARA) - The Globe and Mail
Femasys receives CE Mark approval for FemHSG fertility catheter - Investing.com UK
Femasys updates corporate presentation on women’s health portfolio - TipRanks
Maxim Group Maintains Femasys(FEMY.US) With Buy Rating, Cuts Target Price to $1.5 - Moomoo
Femasys posts updated corporate presentation detailing fertility and FemBloc commercialization plans - TradingView
Femasys (NASDAQ: FEMY) outlines FemaSeed fertility and FemBloc birth control strategy - Stock Titan
Femasys receives CE Mark approval for FemHSG fertility catheter By Investing.com - Investing.com South Africa
Lake Street Remains a Buy on Femasys (FEMY) - The Globe and Mail
Femasys Expands Fertility Care Portfolio In Europe With CE Mark Approval For Femhsg™ Catheter - TradingView
TradingKey - TradingKey
Femasys Reverse Stock Split May Not Prevent Nasdaq Delisting Risk, Observer Warns - The Globe and Mail
Femasys Inc. Announces Financial Results for Quarter Ending March 31, 2026 - geneonline.com
Femasys Inc. Q1 2026 Financials: Revenue Growth, Forward-Looking Statements, and Market Strategy - Minichart
Femasys Inc expected to post a loss of 9 cents a shareEarnings Preview - TradingView
FEMASYS INC 1Q 2026: Revenue $424.9K, Net income $328.6K, EPS $0— 10-Q Summary - TradingView
Non-cash gains lift Femasys (NASDAQ: FEMY) to Q1 profit amid cash strain - Stock Titan
Net income returns at Femasys (NASDAQ: FEMY) as Q1 2026 results filed - Stock Titan
Femasys Announces Financial Results for Quarter Ended March 31, 2026 and Provides Corporate Update - The Manila Times
Femasys starts birth-control trial as it expands fertility care - Stock Titan
Press Release: Femasys Announces Financial Results for Quarter Ended March 31, 2026 and Provides Corporate Update - Moomoo
FEMY SEC FilingsFEMASYS INC 10-K, 10-Q, 8-K Forms - Stock Titan
FEMY | Femasys Inc. Common Stock Insider Trading - Quiver Quantitative
How Femasys (FEMY) maintains its asset base | Q4 2025: Better Than ExpectedWeak Earnings Momentum - newsline.com
Why Femasys (FEMY) valuation makes sense when you dig deeper (Steady Decline) 2026-05-07Earnings Beat Stocks - The Legal Advocate
Femasys pushes fertility treatment into OB/GYN offices with first paid use - Stock Titan
Femasys Enables OB/GYNs to Deliver First-Line Fertility - GlobeNewswire
MSN Money - MSN
The inflation impact visible in Femasys (FEMY) results | Q4 2025: EPS Tops ViewsEPS Guidance Update - newsline.com
Femasys Inc (FEMY) 재무 분석
매출
순이익
현금흐름
주당 순 이익
5.23%
자본화:
|
볼륨(24시간):